Discover careers at the forefront of innovation

Showing 10 companies

Forkhead Bio is harnessing the intrinsic capabilities of cell conversion and regeneration in order to develop transformative therapies that improve patients'​ lives. Our first target indication is insulin-dependent diabetes.
Gencove is a genome center that offers a sequencing platform for genome discovery, exploring microbiomes, and generating ancestry.
Goldilocks Therapeutics was formed to develop drugs to address poorly treated kidney conditions by leveraging the Company’s proprietary mesoscale nanoparticles (MNPs) to specifically target therapeutic payloads to the kidneys. This approach – and the associated sustained release of therapeutic compounds – holds the potential to vastly increase the local concentration of drug at the renal tubules, thereby providing improved efficacy with little or no systemic side effects. Renal diseases of interest include proximal tubule conditions such as acute kidney injury (AKI) and various rare monogenic disorders (such cystinuria, renal tubular acidosis, lysinuric protein intolerance, adenine-phosphoribosyl-transferase deficiency, and Dent disease), as well was the relatively common genetic disorder of the distal tubules, polycystic kidney disease. Further, it is now well recognized that adverse cross talk between the tubules and the glomerulus plays an important role in the progression of chronic kidney disease in all settings, whether there is initial isolated tubulointerstitial injury or combined glomerular/tubular injury. Among these therapeutic indications are autosomal dominant tubulointerstitial kidney disease (ADTKD) as well as chronic kidney disease of different etiologies, including diabetic and hypertensive nephropathy.
Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins. By changing the activity of proteins that modify messenger RNA, we aim to develop new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases. We are applying a 360-degree approach to small molecule drug design to build a pipeline based on the promise of this rapidly emerging biopharmaceutical field.
LEXEO Therapeutics is a fully integrated clinical-stage gene therapy company advancing disease-modifying treatments for genetic cardiovascular conditions and genetic conditions of the central nervous system (CNS). The company aims to apply cutting-edge science to target the underlying causes of both rare monogenic diseases and diseases affecting large patient populations. LEXEO’s current pipeline consists of adeno-associated virus (AAV)-mediated gene therapies in rare cardiac diseases, CLN2 Batten disease, and APOE4-associated Alzheimer’s disease. In addition, the company has more than 15 AAV-mediated gene therapy programs in research and development. LEXEO was founded based on well-established gene therapy research legacy at Weill Cornell Medicine’s Department of Genetic Medicine by a team of pioneering scientists, clinicians, and business leaders with deep expertise in gene therapy. The company is headquartered in New York City.
A better way to make organisms better
96 jobs
OpenTrons is a developer of a pipetting robot technology designed to automate experiments.The company's technology is an automated laboratory equipment that automates experiments by using Python language, enabling scientific researchers to make the process faster and less tiresome.
Patch Bio
Patch Bio
8 jobs
We engineer DNA for gene therapy, using machine learning and massively parallel assays.